Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionChevy Chase Trust Holdings, Inc.
Latest Disclosed Ownership407,615 shares
Latest Disclosed Value $ 182,016,402
Chevy Chase Trust Holdings, Inc. reports 0.18% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Chevy Chase Trust Holdings, Inc. filed a 13F-HR form disclosing ownership of 407,615 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $182,016,402 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 408,363 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -0.18% during the quarter. The current value of the position is $182,134,610 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 407,615 -748 -0.18 182,016 -1.68 0.3805
2026-02-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 408,363 -10,146 -2.42 185,135 12.95 0.5001
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 418,509 -22,418 -5.08 163,905 -16.50 0.4509
2025-07-29 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 440,927 -2,121 -0.48 196,301 -8.61 0.5710
2025-04-23 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 443,048 -1,653 -0.37 214,799 19.94 0.6868
2025-01-30 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 444,701 -2,160 -0.48 179,081 -13.83 0.5452
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 446,861 -6,568 -1.45 207,826 -2.21 0.6370
2024-07-22 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 453,429 9,604 2.16 212,531 14.56 0.6781
2024-05-03 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 443,825 -1,124 -0.25 185,523 2.47 0.6072
2024-01-24 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 444,949 14,311 3.32 181,045 20.90 0.6480
2023-10-23 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 430,638 14,744 3.55 149,750 2.32 0.5915
2023-07-25 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 415,894 77,125 22.77 146,357 37.12 0.5482
2023-05-17 2023-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 338,769 122,740 56.82 106,736 71.09 0.4224
2023-05-16 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,597 -211,432 1,448 0.1978
2023-02-09 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 216,029 59,356 37.89 62,385 37.52 0.2652
2022-11-04 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 156,673 2,149 1.39 45,363 4.18 0.1937
2022-08-10 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 154,524 1,312 0.86 43,543 8.90 0.1801
2022-04-27 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 153,212 462 0.30 39,984 19.20 0.1378
2022-01-31 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 152,750 -6,536 -4.10 33,543 16.09 0.1081
2021-10-20 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 159,286 -5,666 -3.43 28,893 -13.13 0.1007
2021-07-20 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 164,952 -9,520 -5.46 33,259 -11.29 0.1131
2021-04-22 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 174,472 -14,332 -7.59 37,492 -15.98 0.1337
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 188,804 -17,366 -8.42 44,622 -20.46 0.1590
2020-11-06 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 206,170 -15,023 -6.79 56,103 -12.63 0.2217
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 221,193 -7,558 -3.30 64,214 17.97 0.2604
2020-05-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 228,751 2,526 1.12 54,431 9.89 0.2533
2020-02-12 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 226,225 -1,493 -0.66 49,533 28.39 0.1874
2019-11-20 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 227,718 -464 -0.20 38,579 -7.80 0.1582
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 228,182 -1,222 -0.53 41,843 7.08 0.1734
2019-05-13 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 229,404 2,476 1.09 39,078 3.92 0.1616
2019-02-14 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 226,928 -17,032 -6.98 37,604 -20.03 0.1834
2018-10-23 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 243,960 -4,440 -1.79 47,021 11.38 0.1949
2018-08-02 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 248,400 159 0.06 42,218 4.35 0.1829
2018-04-10 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 248,241 -4,775 -1.89 40,458 6.70 0.1798
2018-01-22 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 253,016 -922 -0.36 37,918 -1.79 0.1633
2017-11-14 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 253,938 5,763 2.32 38,608 20.72 0.1749
2017-07-13 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 248,175 4,702 1.93 31,982 20.12 0.1531
2017-04-05 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 243,473 8,933 3.81 26,624 54.08 0.1307
2017-01-09 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 234,540 3 0.00 17,279 -15.52 0.0916
2016-10-05 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 234,537 -4,450 -1.86 20,454 -0.50 0.1119
2016-07-08 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 238,987 3,634 1.54 20,557 9.88 0.1146
2016-04-07 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 235,353 32,721 16.15 18,709 -26.62 0.1070
2016-01-15 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 202,632 2,238 1.12 25,497 22.18 0.1495
2015-10-15 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 200,394 7,682 3.99 20,869 -12.30 0.1303
2015-07-15 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 192,712 3,845 2.04 23,796 6.80 0.1425
2015-04-17 2015-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 188,867 7,734 4.27 22,281 3.55 0.1344
2015-04-15 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 188,867 22,281
2015-01-15 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 181,133 156 0.09 21,518 5.87 0.1345
2014-10-17 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 180,977 12,420 7.37 20,325 27.36 0.1316
2014-07-16 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 168,557 -3,346 -1.95 15,959 31.27 0.1110
2014-04-15 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 171,903 1,557 0.91 12,157 -3.95 0.0871
2014-01-23 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 170,346 2,824 1.69 12,657 -0.35 0.0925
2013-10-15 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 167,522 167,522 12,702 0.1036
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.